Chase Therapeutics competitors

James Fairbairn has 20+ years in senior finance roles with emerging companies. He is a Chartered Professional Accountant, having obtained his CPA designation in 1987 and is an Institute-certified Director. Jim holds a Bachelor of Arts from the University of Western Ontario. He is a director of several junior listed companies.

Dr. James Breitmeyer is the president & CEO Oncternal Therapeutics, Inc., a San Diego cancer biotechnology company. He was instrumental in identifying and acquiring rights to ROR1 technology from UCSD and for developing ETS-family inhibitors based on discoveries from Georgetown University, while assembling Oncternal’s pipeline of oncology therapeutics. Dr. Breitmeyer was a lead author on the research grant submitted to the California Institute for Regenerative Medicine (CIRM) which resulted in the award of $18.3 million to UCSD to support development of lead program cirmtuzumab currently in Phase 1/2 clinical studies. Dr. Breitmeyer believes biomedical research and collaborations with academia are essential for targeting cancers where there are patients with critical unmet needs that aren’t being fully addressed by currently available therapies. At Oncternal, Dr. Breitmeyer is combining drug development expertise with exciting science for a synergistic combination to spur the development of novel product candidates that can potentially be applied across a large number of cancers. Dr. Breitmeyer is board certified in internal medicine and oncology. He holds a bachelor’s degree in chemistry from the University of California and earned M.D. and Ph.D. degrees from Washington University School of Medicine with fellowships at Washington University and Harvard Medical School. He held clinical and teaching faculty positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer has more than 30 years of experience across all aspects of the biotechnology industry in both large and small companies, and across multiple therapeutic areas. He is currently a member of the Boards of Directors of Oncternal Therapeutics Inc, Zogenix Inc, and Otonomy Inc.